|
|
| |
|
|
|
|
AmVac AG| Adress: | Metallstrasse 4
6300 Zug | | Phone: | +41 41 725 32 30 | | Fax: | +41 41 725 32 45 | | Website: | www.amvac.ch | | | | | Contact: | Prof. Melinda-Kinga Karpati, CEO | | Email Direct: | | | Products and services: | AmVac AG (AmVac) is a biopharmaceutical company which is developing (advancing) innovative vaccines against infectious diseases. The company is focused on those indications where large unmet medical needs with an emphasis on safety exist. | | Year of Foundation: | 2005 | | How many in Biotechnology: | 20-49 | | Classification: | Biotech Company
| | Biotech Activities: | Pharmaceuticals / Therapeutics / Vaccines (human)
| | Research & Development: | AmVac will strive to take a leading role in fighting three of the most common diseases in the area of gynecology, urology and respiratory diseases. Femivac was designed to treat vaginal infections. Prostavac was designed to cure benign prostatic hyperplasia (BPH) and chronic prostatitis. Prostavac has the blockbuster-potential to be the first patented vaccine, which can cure and prevent simultaneously both symptoms. Femivac should treat and prevent acute, subacute and chronic vaginal infections from unspecific bacteria and trichomonas. Against respiratory syncytial virus diseases until now no vaccine exists on the market. | | Cooperation possibilities: | The AmVac strategy is to create a fully integrated biopharmaceutical company by maximizing the commercial potential of its product candidates and technologies. These target infectious diseases, for which substantial unmet medical needs for treatment not yet exist. To implement this strategy, AmVac has to decide among different strategic options for each product candidate and technology.:
Targeted stage in value chain (research, development, manufacturing, marketing, sales), Involvement of partners |
<- Zurück |
|
|
|
